As Elan Corporation, plc (NYSE:ELN) and private investment firm Royalty Pharma were sparring over who got to buy Elan, Seth Klarman's Baupost Group decided to take some profits on its investment in the biotechnology company. According to regulatory filings made with the Irish authority, Baupost has slashed its stake in Elan Corporation, plc (NYSE:ELN) from 9.1 million shares to 7.1 million shares. The ownership only represents a 1.39 percent position in Elan Corporation, plc (NYSE:ELN) and the regulatory filing was enforced because Elan is currently a takeover target.
Seth Klarman's Baupost Takes Profit On Stake In Elan Corp
HFA Staff
Premium Members Get EVEN MORE VALUE
Subscribe to Hedge Fund Alpha
Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha
Don’t have an account?
Subscribe and get an extra 30% off annual with code LETTERSThe post above is drafted by the collaboration of the Hedge Fund Alpha Team.